AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
AAPL   323.34 (+0.46%)
MSFT   184.91 (+1.14%)
FB   232.72 (+0.35%)
GOOGL   1,442.31 (+0.52%)
AMZN   2,472.41 (+0.06%)
NVDA   353.01 (+0.22%)
CGC   16.14 (-2.06%)
BABA   214.33 (+3.76%)
MU   46.82 (+1.04%)
GE   7.05 (+4.29%)
TSLA   881.56 (-1.84%)
AMD   53.54 (-0.17%)
T   30.99 (+0.19%)
ACB   14.53 (+3.05%)
F   5.90 (+0.51%)
GILD   73.26 (-2.53%)
DIS   118.75 (-0.02%)
NFLX   427.31 (+0.33%)
BAC   24.84 (+0.93%)
BA   153.31 (+1.27%)
Log in

ASX:CYCCyclopharm Stock Price, Forecast & News

A$1.36
-0.01 (-0.73 %)
(As of 05/13/2020)
Add
Compare
Today's Range
A$1.36
Now: A$1.36
A$1.36
50-Day Range N/A
52-Week Range
A$0.70
Now: A$1.36
A$1.73
Volume10,000 shs
Average VolumeN/A
Market Capitalization$107.79 million
P/E RatioN/A
Dividend Yield0.64%
BetaN/A
Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. It operates through Technegas and Molecular Imaging segments. The company offers diagnostic equipment and consumables, which are used by physicians in the detection of pulmonary embolism. It also provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases; and Ultralute, a patented nuclear medicine technology for use in Mollybdenum-99 generators. The company serves nuclear medicine departments in hospitals and clinics. Cyclopharm Limited is headquartered in Kingsgrove, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 1.7Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.39 out of 5 stars


Industry, Sector and Symbol

Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9541 0411

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$17.01 million
Cash FlowA$0.16 per share
Book ValueA$0.30 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$107.79 million
Next Earnings DateN/A
OptionableNot Optionable

Receive CYC News and Ratings via Email

Sign-up to receive the latest news and ratings for CYC and its competitors with MarketBeat's FREE daily newsletter.

Cyclopharm (ASX:CYC) Frequently Asked Questions

How often does Cyclopharm pay dividends? What is the dividend yield for Cyclopharm?

Cyclopharm declared a Final dividend on Thursday, February 27th. Investors of record on Tuesday, April 7th will be given a dividend of 0.005 per share on Tuesday, April 7th. This represents a yield of 0.52%. The ex-dividend date is Monday, March 30th. View Cyclopharm's dividend history.

Has Cyclopharm been receiving favorable news coverage?

News stories about CYC stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cyclopharm earned a coverage optimism score of -1.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutCyclopharm.

Who are some of Cyclopharm's key competitors?

Who are Cyclopharm's key executives?

Cyclopharm's management team includes the following people:
  • Mr. James S. McBrayer, CEO, MD, Company Sec. & Director (Age 54)
  • Mr. Mathew Farag, Chief Operating Officer
  • Mr. Graham N. Phillips, Fin. Mang.
  • Ms. Sui Ling Cheah, Financial Controller (Age 49)
  • Mr. Lynn McLauchlin, Gen. Mang. of Canada

What is Cyclopharm's stock symbol?

Cyclopharm trades on the ASX under the ticker symbol "CYC."

What is Cyclopharm's stock price today?

One share of CYC stock can currently be purchased for approximately A$1.36.

How big of a company is Cyclopharm?

Cyclopharm has a market capitalization of $107.79 million and generates $17.01 million in revenue each year.

What is Cyclopharm's official website?

The official website for Cyclopharm is www.cyclopharm.com.au.

How can I contact Cyclopharm?

The company can be reached via phone at 61 2 9541 0411.

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.